💔🩸 HF and CKD often coexist. EMR-based decision support can boost GDMT use, flag CKD early (via eGFR & UACR), and guide timely therapy. Integrating AI/ML into EMRs could enable personalized, proactive care for HF + CKD ( https://t.co/3t4StLGxSH). #HREV @nihardesai927 @yaleHFdoc

Black heart transplant recipients experience worse 3-year outcomes including graft failure, rejection, and renal disease progression. #AHAJournals @SA_Hamilton1 https://t.co/HaK6ILpqAm

Here in 📄 paper & ink 🖋️!! The 5th #ECMO specialists training manual: the new ELSO Blue Book 📘 Available at #ELSO2025, starting tomorrow! With all ELSO publications: 📕 The Red Book 6th Edition 📘 Post-cardiotomy #ECLS & temporary MCS in adults 📕 ECPR and Resuscitative #ECMO

Congrats to @ankeetbhatt for KP VACCINATE LBCT @ESC2025. Largest RCT ever conducted with >3.6 million patients randomized in 1 month. No effect on vaccination rates but proof-of-concept for large-scale embedded RCT within a LHS!

A new concept from 2025 ESC guidelines on myocarditis and pericarditis presented: the IMPS (Inflammatory MyoPericardial Syndrome) acronym. A new term to describe the full spectrum of myocardial and pericardial inflammatory diseases and improve the management of patients.

HFpEF is marked by elevated LV filling pressures due to diastolic dysfunction. This review explores how intrathoracic volume & pressure—affected by posture, gravity, obesity, & exercise—shape cardiac filling & highlight research gaps ( https://t.co/yx1EJZSXFB). @JLHarrington_MD

🚨 Funded by a $5M AHA grant, the SCOUT-ECHO-AI (@David_Ouyang) trial will test whether AI can detect early signs of kidney & liver dz from routine TTEs and identify the optimal approach to communicate these findings.( https://t.co/Et1Txy4ASN). @CkmResearch @ankeetbhatt @ATSandhu

📢 Largest study to date of HFimpEF—out in JACC! 🫀 Among >28K new HFrEF patients, 1 in 3 improved to HFimpEF within 12 months ⚠️ Risk remains: • HF events ↓ • Mortality ↓ • GDMT use declined 🔍 Continuing GDMT is critical. @ankeetbhatt @ATSandhu https://t.co/1l742eArY3

Congrats @David_Ouyang on what will be transformational work at the intersection of CKM health, evaluating #opportunistic screening & #ImplementationScience to improve population health!! @American_Heart @HeartDocSadiya @KPDOR https://t.co/UwGmybGLpq

Congratulations to the writing team for the latest ASE guidelines on Diastology

DOACs may offer a safer, simpler alternative to warfarin for LVAD patients—especially with HM3. This review explores emerging data, device-specific considerations, and the need for prospective trials to guide anticoagulation for LVADs ( https://t.co/oHFmG8DFsA). #HREV @ninoskills

FMR is a common HF complication linked to worse outcomes. M-TEER is now backed by RESHAPE-HF2 & MATTERHORN, showing reduced HF events & CVD, plus better safety vs surgery. A shift is underway—from last resort to select earlier use. ( https://t.co/ePGnyjVa9e). #HREV @SotiriaLiori

HFpEF affects ~4M in the U.S. Once lacking therapies, HFpEF is now seeing rapid progress—with SGLT2i, Ns-MRAs, and GLP-1 RAs offering hope, especially for the obesity phenotype. ( https://t.co/ZoPAlaDhHn). #HREV @JLHarrington_MD @MarcBonaca @AndrewJSauer @orlyvardeny @me_canonico

👏🏼👏🏼👏🏼 bravo @ankeetbhatt

HFpEF is a growing public health burden with few proven therapies. Exercise training improves function, with modalities ranging from moderate-intensity to multi-modal and emerging options like IMT and FES. ( https://t.co/jXJGgxec44). @aepetersMD @JLHarrington_MD

Unplanned admissions for WHF are the costliest part of care. This review explores how invasive & non-invasive pressure sensing—aided by AI—can personalize treatment, detect congestion earlier, and prevent decompensation ( https://t.co/R8GvLu1Z0S). #HREV @dranulala @AndrewJSauer

Outstanding sci. statement from @HeartDocSadiya @dmljmd et al on primary prev of HF. #PREVENTHF now enrolling, studying ASi+SGLT2i in >11k at risk participants, highlighting a new era for HF PREVENTION! https://t.co/6mpVBR1GBX @mvaduganathan @scottdsolomon @MajaCikes @TorBiering

At the @ACCinTouch conference @HCPLiveNews asked @ankeetbhatt @KPDOR @kpnorcal @PermanenteDocs what he's looking forward to in #cardiology for the rest of 2025. Here's what he had to say: https://t.co/bOZLSsuJIh

HFpEF remains tough to treat—with high residual risk & few meds that work. Device-based therapies offer new hope, targeting unique mechanisms (structural, autonomic, EP, RPM). Great summary by friend & former co-fellow @FudimMarat! https://t.co/fN2oAjJVsY Read #HREV @vkittipibul

3 Pillars of Medical Therapy for HFmrEF/HFpEF *⃣ SGLTi + nsMRA + GLP-1 RA (if obesity) *⃣ The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay. @gcfmd @JavedButler1 @DCRINews @JAMACardio https://t.co/yNDUGCJw4P